On October 7, 2024 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its research collaborators at Meharry Medical College were selected to present at the upcoming 39thAnnual Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Meeting being held November 6-10, 2024 in Houston, Texas (Press release, Genprex, OCT 7, 2024, View Source [SID1234647054]). The collaborators will present a poster on positive preclinical data from a study of the Company’s lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid) evaluating TUSC2’s role in modulating immune responses in cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The body of preclinical evidence supporting REQORSA’s potential in the treatment of a variety of cancers continues to grow as we bolster our robust research program for REQORSA with our collaborators at many academic institutions," said Ryan Confer, President and Chief Executive Officer at Genprex. "We are very pleased that our academic partners have been selected to present their findings on REQORSA at this prestigious cancer meeting, and we look forward to this presentation next month sharing more about TUSC2’s role in modulating immune responses in cancer."
The featured Genprex-supported poster to be presented at the 2024 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting:
Title: "TUSC2 Modulates Cancer Immune Responses"
Collaborator: Meharry Medical College
TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company’s Oncoprex Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.